HUTCHMED (NASDAQ:HCM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
A number of other analysts have also weighed in on the stock. Weiss Ratings upgraded shares of HUTCHMED from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 20th. The Goldman Sachs Group decreased their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. HSBC upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. Finally, Daiwa Securities Group upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research note on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.87.
Check Out Our Latest Analysis on HCM
HUTCHMED Price Performance
HCM stock opened at $14.90 on Friday. The company has a 50 day simple moving average of $14.06 and a 200 day simple moving average of $13.20. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $16.33. The company has a current ratio of 5.64, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06.
Hedge Funds Weigh In On HUTCHMED
A number of hedge funds have recently modified their holdings of the business. Janney Montgomery Scott LLC bought a new stake in shares of HUTCHMED in the first quarter worth $365,000. XY Capital Ltd increased its holdings in HUTCHMED by 115.2% in the second quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after purchasing an additional 55,736 shares during the period. Crossmark Global Holdings Inc. raised its position in HUTCHMED by 25.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company’s stock worth $1,553,000 after purchasing an additional 21,270 shares during the last quarter. Finally, Amundi raised its position in HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.
About HUTCHMED
HUTCHMED is a biopharmaceutical company focused on discovering, developing and commercializing medicines, particularly targeted therapies for cancer. Founded in 2000 as Hutchison China MediTech, the company adopted the HUTCHMED name in 2021. Its oncology medicines include fruquintinib, marketed in China as Elunate and in the United States and other markets as Fruzaqla through a partner; surufatinib, marketed in China as Sulanda; and savolitinib, marketed in China as Orpathys. The company also maintains a pipeline of investigational medicines for cancer and immunological diseases.
Further Reading
- Five stocks we like better than HUTCHMED
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
